Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis

Mycobacterium tuberculosis is a major global pathogen. In this trial in sub-Saharan Africa, a new vaccine was found to have 54% efficacy against the development of active pulmonary M. tuberculosis in infected adults.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2018-10, Vol.379 (17), p.1621-1634
Hauptverfasser: Van Der Meeren, Olivier, Hatherill, Mark, Nduba, Videlis, Wilkinson, Robert J, Muyoyeta, Monde, Van Brakel, Elana, Ayles, Helen M, Henostroza, German, Thienemann, Friedrich, Scriba, Thomas J, Diacon, Andreas, Blatner, Gretta L, Demoitié, Marie-Ange, Tameris, Michele, Malahleha, Mookho, Innes, James C, Hellström, Elizabeth, Martinson, Neil, Singh, Tina, Akite, Elaine J, Khatoon Azam, Aisha, Bollaerts, Anne, Ginsberg, Ann M, Evans, Thomas G, Gillard, Paul, Tait, Dereck R
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Clinical medicine
Clinical trials
HIV
Human immunodeficiency virus
Influenza
Information sharing
Injection
Interferon
Lung diseases
Population
Sputum
Tuberculosis
Vaccine efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mycobacterium tuberculosis is a major global pathogen. In this trial in sub-Saharan Africa, a new vaccine was found to have 54% efficacy against the development of active pulmonary M. tuberculosis in infected adults.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1803484